1-5 of 5
Ajoy K. Samanta, PhD
Close
Sort by
Journal Articles

Jak2 Phosphorylates Tyr 177 of Bcr-Abl Activating the Ras and PI-3 Kinase Pathways and Maintains Functional Levels of Bcr-Abl in Chronic Myelogenous Leukemia.

Ajoy K. Samanta, PhD, Sandip N. Chakraborty, Xiaoping Sun, M.D., Ph.D, Ellen Schlette, M.D., Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, PhD
Journal: Blood
Blood (2009) 114 (22): 39.
https://doi.org/10.1182/blood.V114.22.39.39
Published: 2009
Journal Articles

Disruption of the Bcr-Abl/Jak2/HSP90 Network Complex Leading to Induction of Apoptosis in Drug-Resistant CML Cells by a New Compound WP1193

Ajoy K. Samanta, PhD, Sandip N. Chakraborty, Susmita Samanta, Ph.D., Yan Wang, M.D., Xiaoping Sun, MD, PhD, E. Schlette, Waldemar Priebe, Ph.D., Ralph B. Arlinghaus, PhD
Journal: Blood
Blood (2008) 112 (11): 3199.
https://doi.org/10.1182/blood.V112.11.3199.3199
Published: 2008
Journal Articles

Jak2 Regulates Lyn Tyrosine Kinase through Interference with the SET/PP2A/Shp1 Pathway and Inhibition of Jak2 Induced Apoptosis in BCR-ABL+ Imatinib-Sensitive and Resistant CML Cells.

Ajoy K. Samanta, PhD, Sandip Chakravorty, MS, Yan Wang, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Richard E. Champlin, MD, Danilo Perrotti, MD, PhD, Ralph B. Arlinghaus, PhD
Journal: Blood
Blood (2007) 110 (11): 3342.
https://doi.org/10.1182/blood.V110.11.3342.3342
Published: 2007
Journal Articles

Oncogenic Transformation of NIH 3T3 Fibroblasts by BCR-ABL Oncoprotein Requires the IL-3 Receptor.

Wenjing Tao, PhD, Hui Lin, MD, Tong Sun, MS, Ajoy K. Samanta, PhD, Ralph B. Arlinghaus, PhD
Journal: Blood
Blood (2007) 110 (11): 3370.
https://doi.org/10.1182/blood.V110.11.3370.3370
Published: 2007
Journal Articles

Jak2: A Potential Therapeutic Target for Chronic Myelogenous Leukemia (CML).

Ajoy K. Samanta, PhD, Hui Lin, M.D., Tong Sun, M.S., Hagop Kantarjian, M.D., Ralph B. Arlinghaus, Ph.D.
Journal: Blood
Blood (2006) 108 (11): 2121.
https://doi.org/10.1182/blood.V108.11.2121.2121
Published: 2006